Mouse Anti-AHNAK Recombinant Antibody (CBT3427) (V2LY-0625-LY1845)

Kim, Y. N., Shin, J. H., Kyeong, D. S., Cho, S. Y., Kim, M. Y., Lim, H. J., ... & Seong, J. K. (2021). Ahnak deficiency attenuates high-fat diet-induced fatty liver in mice through FGF21 induction. Experimental & molecular medicine, 53(3), 468-482.

Cho, W. C., Jang, J. E., Kim, K. H., Yoo, B. C., & Ku, J. L. (2020). SORBS1 serves a metastatic role via suppression of AHNAK in colorectal cancer cell lines. International journal of oncology, 56(5), 1140-1151.

Zhang, Z., Liu, X., Huang, R., Liu, X., Liang, Z., & Liu, T. (2019). Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition. Journal of Cancer, 10(16), 3860.

Lee, H., Kim, K., Woo, J., Park, J., Kim, H., Lee, K. E., ... & Ryu, H. S. (2018). Quantitative proteomic analysis identifies AHNAK (neuroblast differentiation-associated protein AHNAK) as a novel candidate biomarker for bladder urothelial carcinoma diagnosis by liquid-based cytology. Molecular & Cellular Proteomics, 17(9), 1788-1802.

Zhao, Z., Xiao, S., Yuan, X., Yuan, J., Zhang, C., Li, H., ... & Liu, Q. (2017). AHNAK as a prognosis factor suppresses the tumor progression in glioma. Journal of Cancer, 8(15), 2924.

Chen, B., Wang, J., Dai, D., Zhou, Q., Guo, X., Tian, Z., ... & Xie, X. (2017). AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. Journal of Experimental & Clinical Cancer Research, 36(1), 1-11.

Cho, W. C., Jang, J. E., & Ku, J. L. (2017). SORBS1-AHNAK complex regulates metastatic properties of cancer.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols